SE0401578D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0401578D0
SE0401578D0 SE0401578A SE0401578A SE0401578D0 SE 0401578 D0 SE0401578 D0 SE 0401578D0 SE 0401578 A SE0401578 A SE 0401578A SE 0401578 A SE0401578 A SE 0401578A SE 0401578 D0 SE0401578 D0 SE 0401578D0
Authority
SE
Sweden
Prior art keywords
hydrogen
methyl
fluoro
chloro
alkyl
Prior art date
Application number
SE0401578A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Bjoerk
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0401578A priority Critical patent/SE0401578D0/xx
Publication of SE0401578D0 publication Critical patent/SE0401578D0/xx
Priority to ES05753986T priority patent/ES2294721T3/es
Priority to RU2007101702/04A priority patent/RU2374250C2/ru
Priority to US11/152,777 priority patent/US7553849B2/en
Priority to DE602005002847T priority patent/DE602005002847T2/de
Priority to ZA200609265A priority patent/ZA200609265B/en
Priority to CA2570506A priority patent/CA2570506C/en
Priority to CN2005800199955A priority patent/CN1980937B/zh
Priority to AT05753986T priority patent/ATE375353T1/de
Priority to PCT/EP2005/052767 priority patent/WO2005123744A1/en
Priority to AU2005254731A priority patent/AU2005254731B2/en
Priority to JP2007515955A priority patent/JP4906718B2/ja
Priority to EP05753986A priority patent/EP1776369B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0401578A 2004-06-18 2004-06-18 Novel compounds SE0401578D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0401578A SE0401578D0 (sv) 2004-06-18 2004-06-18 Novel compounds
EP05753986A EP1776369B1 (en) 2004-06-18 2005-06-15 Thienopyridone carboxamides and their medical use
DE602005002847T DE602005002847T2 (de) 2004-06-18 2005-06-15 Thienopyridoncarbonsäureamide und deren medizinische verwendung
RU2007101702/04A RU2374250C2 (ru) 2004-06-18 2005-06-15 Тиенопиридон карбоксамиды и их применение в медицине
US11/152,777 US7553849B2 (en) 2004-06-18 2005-06-15 Compounds
ES05753986T ES2294721T3 (es) 2004-06-18 2005-06-15 Tienopiricarboxamidas y su utilizacion medica.
ZA200609265A ZA200609265B (en) 2004-06-18 2005-06-15 Thienopyridone carboxamides and their medical use
CA2570506A CA2570506C (en) 2004-06-18 2005-06-15 Thienopyridone carboxamides and their medical use
CN2005800199955A CN1980937B (zh) 2004-06-18 2005-06-15 噻吩并吡啶酮甲酰胺及其医药用途
AT05753986T ATE375353T1 (de) 2004-06-18 2005-06-15 Thienopyridoncarbonsäureamide und deren medizinische verwendung
PCT/EP2005/052767 WO2005123744A1 (en) 2004-06-18 2005-06-15 Thienopyridone carboxamides and their medical use
AU2005254731A AU2005254731B2 (en) 2004-06-18 2005-06-15 Thienopyridone carboxamides and their medical use
JP2007515955A JP4906718B2 (ja) 2004-06-18 2005-06-15 チエノピリドンカルボキサミド及びその医学的使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401578A SE0401578D0 (sv) 2004-06-18 2004-06-18 Novel compounds

Publications (1)

Publication Number Publication Date
SE0401578D0 true SE0401578D0 (sv) 2004-06-18

Family

ID=32906817

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401578A SE0401578D0 (sv) 2004-06-18 2004-06-18 Novel compounds

Country Status (13)

Country Link
US (1) US7553849B2 (es)
EP (1) EP1776369B1 (es)
JP (1) JP4906718B2 (es)
CN (1) CN1980937B (es)
AT (1) ATE375353T1 (es)
AU (1) AU2005254731B2 (es)
CA (1) CA2570506C (es)
DE (1) DE602005002847T2 (es)
ES (1) ES2294721T3 (es)
RU (1) RU2374250C2 (es)
SE (1) SE0401578D0 (es)
WO (1) WO2005123744A1 (es)
ZA (1) ZA200609265B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013004169A (es) 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.
CN102127091B (zh) * 2010-12-30 2012-11-21 天津药物研究院 含有杂环的希夫碱化合物
US20220041616A1 (en) * 2018-11-20 2022-02-10 The National Institutes of Pharmaceutical R&D Co., Ltd. Spiro compound and medical uses thereof
CN114957278B (zh) * 2021-02-20 2023-08-11 兰州大学 胰高血糖素受体拮抗剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219864A (en) * 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
DE4227747A1 (de) * 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
GB9311562D0 (en) * 1993-06-04 1993-07-21 Fujisawa Pharmaceutical Co Heterocyclic derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
AU759875B2 (en) 1999-03-09 2003-05-01 Pharmacia & Upjohn Company 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
CN1545412A (zh) 2001-08-24 2004-11-10 ������ҩ��ʽ���� 预防和治疗便秘型肠道易激综合症的药物
AR038294A1 (es) 2002-01-14 2005-01-12 Upjohn Co Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
WO2004019939A1 (en) 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis

Also Published As

Publication number Publication date
JP2008502655A (ja) 2008-01-31
RU2374250C2 (ru) 2009-11-27
US20060004038A1 (en) 2006-01-05
DE602005002847T2 (de) 2008-07-10
EP1776369B1 (en) 2007-10-10
US7553849B2 (en) 2009-06-30
WO2005123744A1 (en) 2005-12-29
JP4906718B2 (ja) 2012-03-28
AU2005254731A1 (en) 2005-12-29
CN1980937A (zh) 2007-06-13
DE602005002847D1 (de) 2007-11-22
EP1776369A1 (en) 2007-04-25
RU2007101702A (ru) 2008-07-27
ES2294721T3 (es) 2008-04-01
ZA200609265B (en) 2008-05-28
AU2005254731B2 (en) 2010-10-21
CA2570506C (en) 2012-12-18
CA2570506A1 (en) 2005-12-29
ATE375353T1 (de) 2007-10-15
CN1980937B (zh) 2011-08-10

Similar Documents

Publication Publication Date Title
SE9802549D0 (sv) Quinoline derivatives
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
ECSP088179A (es) Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos
RS53075B (en) 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
TW200744575A (en) Methods of treating epileptogenesis
CY1110145T1 (el) Αλκυλο-υποκατεστημενες ινδολοκινοξαλινες
MY157373A (en) Carbamate compounds for use in preventing or treating movement disorders
RS67403A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
DE602005002847D1 (de) Thienopyridoncarbonsäureamide und deren medizinische verwendung
DK1408953T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom
EA200700871A1 (ru) Способы нейропротекции
MY136391A (en) Carbamate compounds for use in preventing or treating anxiety disorders
RS67503A (en) Carbamate compounds for use in preventing of treating psychotic disorders
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов
SE0400441D0 (sv) Novel Benzofurans and Indols
PL422539A1 (pl) Związki N-arylosulfonyloindolowe do leczenia chorób OUN
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
TH70879A (th) อนุพันธ์ของ 5-(ไพริดิน-3-อิล)-1-แอซาไบไซโคล[3.2.1]ออกเทน, การเตรียมสาร และการประยุกต์ใช้สารในการบำบัดรักษา
AR035699A1 (es) Asociacion de al menos un derivado de piridoindolona, composicion farmaceutica que comprende al menos un derivado de piridoindolona y kit para el tratamiento de la proliferacion de celulas tumorales